Padhi Aditya K, Tripathi Timir
Brief Funct Genomics. 2023 Apr 13;22(2):195-203. doi: 10.1093/bfgp/elac020.
Most pathogens mutate and evolve over time to escape immune and drug pressure. To achieve this, they alter specific hotspot residues in their intracellular proteins to render the targeted drug(s) ineffective and develop resistance. Such hotspot residues may be located as a cluster or uniformly as a signature of adaptation in a protein. Identifying the hotspots and signatures is extremely important to comprehensively understand the disease pathogenesis and rapidly develop next-generation therapeutics. As experimental methods are time-consuming and often cumbersome, there is a need to develop efficient computational protocols and adequately utilize them. To address this issue, we present a unique computational protein design protocol that identifies hotspot residues, resistance mutations and signatures of adaptation in a pathogen's protein against a bound drug. Using the protocol, the binding affinity between the designed mutants and drug is computed quickly, which offers predictions for comparison with biophysical experiments. The applicability and accuracy of the protocol are shown using case studies of a few protein-drug complexes. As a validation, resistance mutations in severe acute respiratory syndrome coronavirus 2 main protease (Mpro) against narlaprevir (an inhibitor of hepatitis C NS3/4A serine protease) are identified. Notably, a detailed methodology and description of the working principles of the protocol are presented. In conclusion, our protocol will assist in providing a first-hand explanation of adaptation, hotspot-residue variations and surveillance of evolving resistance mutations in a pathogenic protein.
大多数病原体随着时间的推移会发生突变和进化,以逃避免疫和药物压力。为实现这一目的,它们会改变细胞内蛋白质中的特定热点残基,使靶向药物失效并产生耐药性。此类热点残基可能成簇分布,也可能均匀分布,作为蛋白质适应性的一种特征。识别这些热点和特征对于全面了解疾病发病机制以及快速开发下一代治疗方法极为重要。由于实验方法耗时且往往繁琐,因此需要开发高效的计算方案并充分加以利用。为解决这一问题,我们提出了一种独特的计算蛋白质设计方案,该方案可识别病原体蛋白质中针对结合药物的热点残基、耐药突变和适应性特征。使用该方案,可以快速计算设计的突变体与药物之间的结合亲和力,从而为与生物物理实验进行比较提供预测。通过对一些蛋白质-药物复合物的案例研究展示了该方案的适用性和准确性。作为验证,我们识别了严重急性呼吸综合征冠状病毒2主要蛋白酶(Mpro)对那洛普韦(一种丙型肝炎NS3/4A丝氨酸蛋白酶抑制剂)的耐药突变。值得注意的是,本文还介绍了该方案的详细方法和工作原理说明。总之,我们的方案将有助于对致病蛋白质中的适应性、热点残基变异以及不断演变的耐药突变监测提供第一手解释。